PBS: Lyme & Vaccine

  Approx. 6 Min  Published on Jun 29, 2017

This is peak season in the United States for Lyme disease, as people spend more time outdoors and can be at risk for tick bites.

Each year, at least 30,000 cases are reported, and researchers believe those estimates are low. Given its debilitating effects on some people, and after years of research, it begs the question: Why is there still no vaccine people can get to prevent Lyme disease?

Miles O’Brien has been exploring that for his weekly reports on the Leading Edge of science and technology.

KYRAN ROMANOWSKI: I’m nervous. I’m not particularly thrilled having 30 ticks in my arm.

Kyran Romanowski was diagnosed with Lyme disease in June of 2016. His symptoms, achy joints, fatigue and memory recall lapses, have persisted long after he stopped taking antibiotics.

KYRAN ROMANOWSKI: Why am I still having these symptoms when I had all these courses of treatment? You know, is the bacteria still in my body? I don’t know.

Neither do doctors. About 10 percent to 15 percent of people who get Lyme report stubborn symptoms for months, even years, even after antibiotic treatment. Is it lingering damage from Lyme? Are the body’s natural defenses stuck in attack mode? Or is it something else?

DR. LINDEN HU: So, another possibility is that the bacteria persist, and they haven’t been eradicated by the antibiotic treatment, and that the immune system may still be recognizing them and fighting them and causing symptoms of inflammation and infection.

Could the Lyme disease bacteria, Borrelia burgdorferi, be cleverly hiding inside the human body? Doctors cannot detect the organisms using existing blood tests, but Dr. Hu hopes Borrelia and ticks are like magnet and steel.

DR. LINDEN HU: The bacteria are so well-adapted to their natural vector, the tick, that they’re able to sense the tick, and the tick acts as a concentrating vessel to allow you to better sample what’s in the host.

After removing these ticks, Dr. Hu will grind them up and test them for the Lyme bacteria.

The ticks have been bred in the lab, under sterile conditions, so if Borrelia is there, it can only have come from the patient. Deploying ticks as bacteria detectors may seem far from a practical test, but it could give researchers some ideas on how to devise one.

Rheumatologist Allen Steere and his team at Massachusetts General Hospital are working on better tests and treatments as well. His lab is filled with more than 40 years of blood, cells and tissues samples from Lyme suffers.

In 1975, Steere was the investigator who first connected the dots between a cluster of children with symptoms of arthritis in Lyme, Connecticut, and what came to be known as Lyme disease.

DR. ALLEN STEERE, Massachusetts General Hospital: My career has largely been focused on the elucidation of Lyme disease in human patients, what it’s like clinically, development of diagnostic test and treatment strategies with various courses antibiotic therapy, but then also prevention of the disease by vaccination.

The Lyme disease vaccine which he helped develop is a sore subject. Sold under the brand name LYMErix by SmithKline Beecham, now GlaxoSmithKline, it was first prescribed in 1998.  (see comment after article)

It was 80 percent effective at stemming the disease. But hundreds of recipients claimed the vaccine made their Lyme symptoms worse. Federal investigators found no scientific proof the vaccine was the cause of their complaints, but anti-vaccine advocacy groups threatened class-action lawsuits, and sales plummeted.

In 2002, SmithKline took LYMErix off the market.

DR. ALLEN STEERE: And I think the time has come to reconsider the decision. Lyme disease is the only infection that I know of for which there is an effective vaccine, but it’s not available to the public.

Unless you happen to be a dog.

It sure seems like something we should be working on to prevent, one way or another.

In fact, the French biotech firm Valneva is in the first phase of U.S. Food and Drug Administration testing on a new vaccine that is similar to LYMErix. 

In the 15 years since the vaccine was pulled off the market, Lyme has exploded into an epidemic; 300,000 people get it every year.

**Comment**

Let’s talk about the Lyme vaccine pulled from the market due to “lack of demand.”

Did you know that the LYMERIX vaccine caused 640 emergency room visits, 34 life threatening reactions, 77 hospitalizations, 198 disabilities, and 6 deaths? In a vile cesspool of conflicts of interest are university patent holders, drug companies, and the FDA itself as another patent holder. It generated 40 million dollars before it was yanked. (2008, Drymon)
http://www.yourlawyer.com/topics/overview/lymerix One doctor stated that 21 patients developed severe arthritis after receiving the LYMERIX vaccine.
http://www.lymediseaseassociation.org/index.php/about-lyme/controversy/vaccine/261-lymerix-meeting   “Given that Dr. Marks lead the clinical trials for Lymerix’s competitor, the OspA vaccine produced and then abandoned by Aventis Pasteur, his conclusions mean a lot. “In my opinion,” he told FDA officials, there is sufficient evidence that Lymerix is causally related to severe rheumatologic, neurologic, autoimmune, and other adverse events in some individuals. This evidence is such as to warrant a significantly heightened degree of warnings and possible limitations or removal from marketing of Lymerix.”

https://madisonarealymesupportgroup.com/2017/01/26/lyme-vaccine-to-be-tested-on-humans/  The biological mechanism hypothesis was that the outer surface protein A (OspA), which was the antigenic component of the LYMErix vaccine, induced autoimmunity in genetically susceptible individuals, including high levels of autoantibody to OspA in their synovial fluid.

Dr. Stricker states:

Another Lyme OspA Vaccine Whitewash
The meta-analysis by Zhao and colleagues comes to the conclusion that “the OspA vaccine against Lyme disease is safe and its immunogenicity and efficacy have been verified.” The authors arrive at this sunny conclusion by excluding 99.6% of published articles that demonstrate potential problems with the OspA vaccine. Furthermore, the authors ignore peer-reviewed studies, FDA regulatory meetings and legal proceedings that point to major problems with OspA vaccine safety (1-3). This whitewash bodes ill for future Lyme vaccine candidates because it fosters disregard for vaccine safety among Lyme vaccine manufacturers and mistrust among potential Lyme vaccinees.

Also, I find it highly intriguing that the push here, and always, is for a vaccine; not a cure, not helping patients with pain, not making care accessible and affordable.  Just in creating a new cash-cow.

Despite Lyme disease bring one of the fastest spreading infectious diseases in the world, and is almost twice as common as breast cancer and six times more common than HIV/AIDS, you can keep your vaccine, Mr. Steere.